Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.

Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.

BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market. 

Susan Rienow, UK country president of Pfizer, is to formally replace Pinder Sahota, UK manager of Novo Nordisk, as president of the UK pharmaceutical industry trade group, the ABPI.

Brazil’s medicines regulator Anvisa is considering new rules that would define regulatory reliance procedures for inspections and good manufacturing practice certification.

The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.